Vim Gene plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
VIM (Vimentin) encodes a type III intermediate filament protein that is one of the most widely expressed structural proteins in eukaryotic cells. While classically associated with mesenchymal cells, vimentin plays important roles in neuronal function, glial biology, and has been increasingly recognized in neurodegenerative disease pathogenesis.
| Vimentin | |
|---|---|
| Gene Symbol | VIM |
| Full Name | Vimentin |
| Chromosome | 10p13 |
| NCBI Gene ID | 7431 |
| OMIM | 193060 |
| Ensembl ID | ENSG00000026025 |
| UniProt ID | P08670 |
| Associated Diseases | Alzheimer's Disease, Parkinson's Disease, ALS, Cataracts |
The VIM gene spans approximately 9 kb on chromosome 10p13 and consists of 9 exons encoding a 466-amino acid protein with a molecular weight of ~57 kDa. The protein contains:
The rod domain contains the characteristic heptad repeats that drive dimerization and filament assembly.
Vimentin intermediate filaments serve multiple essential cellular functions:
While primarily a mesenchymal intermediate filament, vimentin is expressed in:
Vimentin is prominently involved in AD pathogenesis through several mechanisms:
Neurofibrillary Tangle Formation
Vimentin is incorporated into abnormal filamentous inclusions in AD brains. The protein undergoes post-translational modifications (hyperphosphorylation, oxidation) that promote aggregation. These vimentin-positive inclusions colocalize with tau pathology, suggesting a shared mechanism of intermediate filament dysfunction in AD [1].
Glial Activation
Reactive astrocytes expressing vimentin surround amyloid plaques in AD brains. This glial response may be both protective (clearance) and pathological (inflammatory cytokine release). Vimentin-positive astrocytes show increased GFAP expression, marking the transition to a reactive phenotype [2].
Axonal Transport Defects
Vimentin dysfunction may contribute to axonal transport impairments in AD. The filament network normally supports organelle motility; its disruption could exacerbate amyloid-beta-induced transport deficits.
In PD, vimentin pathology is less prominent than in AD but still relevant:
Glial Activation
Vimentin-positive glia are elevated in the substantia nigra of PD patients. This reflects ongoing neuroinflammation, with vimentin serving as a marker of activated microglia and astrocytes [3].
Potential Lewy Body Involvement
Some studies report vimentin in Lewy bodies, the characteristic alpha-synuclein inclusions of PD. This suggests vimentin may be recruited into protein aggregates during disease progression.
Intermediate Filament Accumulation
ALS features accumulation of neurofilament proteins; vimentin is often co-deposited in these aggregates. Mutations in neurofilament light chain (NEFL) and other intermediate filament genes cause ALS-like syndromes [4].
Astrocytic Reactivity
Vimentin-expressing astrocytes are prominent in ALS spinal cord. This reactive gliosis precedes motor neuron death and may contribute to disease spread.
Vimentin represents a potential therapeutic target:
| Tissue/Cell Type | Expression Level | Notes |
|---|---|---|
| Fibroblasts | High | Primary expression site |
| Endothelial Cells | Moderate | Vascular cells |
| Astrocytes | Low (baseline), High (reactive) | Disease-associated |
| Schwann Cells | Moderate | Peripheral nerve |
| Neurons | Very Low | Mainly developmental |
Vimentin interacts with numerous proteins:
Vimentin knockout mice are viable but show:
These models have been used to study vimentin's role in neuroinflammation and neurodegeneration.
Vim Gene plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
The study of Vim Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.